Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients
نویسندگان
چکیده
منابع مشابه
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
BACKGROUND This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second-line chemotherapy for taxane-refractory, hormone-refractory, prostate cancer (HRPC). METHODS Patients with HRPC that progressed during or within 60 days of cessation of taxane chemotherapy were randomly selected with equal probability to ixabepilone 35 mg/m(2...
متن کاملDocetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel
PURPOSE This study was undertaken to investigate the outcomes associated with docetaxel treatment of Korean patients with hormone-refractory prostate cancer (HRPC) and to compare its clinical efficacies in 1st and 2nd-line settings. PATIENTS AND METHODS This study was retrospectively performed and included 47 patients with HRPC. The 1st-line group consisted of 19 patients who had not undergon...
متن کاملKetoconazole retains activity in patients with docetaxel-refractory prostate cancer.
Preclinical and clinical data support the importance of signaling via the androgen receptor even in the setting of castration-resistant prostate cancer. However, the role of additional hormonal manipulations in patients progressing on cytotoxic chemotherapy has not been well defined. Recently, the novel lyase inhibitor, abiraterone acetate, has shown activity in patients with docetaxel-refracto...
متن کاملDocetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Three-weekly docetaxel chemotherapy with prednisolone is now considered standard of care for patients with metastatic hormone refractory prostate cancer (MHRPC). This study reports the efficacy and toxicity of first-line docetaxel chemotherapy followed subsequently by re-treatment on biochemical disease progression (BDP). Forty-two patients with MHRPC were treated with three-weekly docetaxel ch...
متن کاملthe role of intermittent chemotherapy in the survival of patients with hormone refractory prostate cancer
introduction: prostate cancer is one of the most common cancers among males and the second factor resulting to death due to cancer among them.(1) the median age of its diagnosis is 65 years. the initial treatment includes androgen ablation or orchiectomy.(2, 3) in case of patient’s hormone refractory, chemotherapy would be substituted. the objective of this study is the consideration of intermi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2007
ISSN: 0008-543X,1097-0142
DOI: 10.1002/cncr.22811